Treatment Delivery Validation
Fig. 15.1 (a) The average chart for the clinical case. Subgroup size of four is used to verify the constancy of the flatness and symmetry. (b) The range chart of…
Fig. 15.1 (a) The average chart for the clinical case. Subgroup size of four is used to verify the constancy of the flatness and symmetry. (b) The range chart of…
Fig. 1.1 Categories of machine learning algorithms according to training data nature From a concept learning perspective, machine learning can be categorized into transductive and inductive learning [27]. Transductive learning…
Fig. 1 Platinum complexes which entered clinical trials While most of the platinum drugs have to be administered intravenously, Satraplatin (8) was the first orally applicable platinum agent under clinical…
Fig. 1 Lung cancer incidence and mortality rates by sex and age, United States, 2006–2010. Rates are per 100,000 and age-adjusted to the 2000 U.S. standard population During 2006–2010, the…
Fig. 1 KRAS signaling. KRAS acts to integrate external signals from extracellular ligands that bind transmembrane growth factor receptors. The KRAS protein is localized to the cell membrane via farnesylation…
Drug name Generic name Target Status Reversible ZD1839 Gefitinib EGFR Approved OSI776 Erlotinib EGFR Approved BPI-2009H Icotinib EGFR Approved TAK-165 Mubritinib EGFR/ERBB2 Phase I XL647 NA EGFR/ERBB2/FLT-4 Phase II…
Risk factor Risk ratio Comments References Second hand smoke 1.34 Prospective nested case control in Europe [27] 1.23 (spouse) 1.27 (workplace) Pooled analysis from two case controls US & Europe…
Fig. 1 A simplified overview of platinum resistance in lung cancer. Pt platinum, CTR1 copper transporter 1, GSH glutathione, BCRP breast cancer resistance protein Table 1 Tumor factors contributing to…
Fig. 1 Vascular endothelial growth factor receptor signal transduction (Reprinted with permission from Roskoski. CROH 2007 62(3):179–213) The role of serum VEGF (VEGF-A) in tumor growth and development has been…